Piazzolla Annarita Valeria

La Dr.ssa Annarita Valeria Piazzolla si è laureata in Biologia ed ha conseguito la Specializzazione in Biochimica-Clinica. Dal 2006, presso il laboratorio di Epatologia, si occupa della valutazione della risposta al trattamento antivirale in pazienti affetti da HCV attraverso l'analisi della correlazione genotipo-fenotipo. Si dedica inoltre allo studio delle tecniche non invasive della fibrosi.

Informazioni aggiuntive

  • Pubblicazioni Scientifiche:

    Totale pubblicazioni a partire dal 2011: 28


    Anno

    2019; 8(4):

    SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.

    Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A


    2019; 14(5): e0215783

    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

    Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangolo A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, C


    2018; ():

    Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

    Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latan


    2018; 154(6): 1764-1777.e7

    TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

    Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C


    2018; 13(7): e0200568

    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.

    Mangia A, Losappio R, Cenderello G, Potenza D, Mazzola M, De Stefano G, Terreni N, Copetti M, Minerva N, Piazzola V, Bacca D, Palmieri V, Sogari F, Santoro R


    2017; 67(4): 680-686

    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.

    Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C


    2017; 46(6): 629-630

    Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.

    Mangia A, Piazzolla V, Santoro R


    2017; 46(4): 424-431

    Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

    Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G


    2016; ():

    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.

    Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M


    2016; 36(7): 971-6

    The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.

    Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM


    2014; 46S5(): S179-S185

    Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies.

    Mangia A, Piazzolla V


    2014; 9(10): e110284

    Individualized treatment of genotype 1 naïve patients: an italian multicenter field practice experience.

    Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M


    2014; 34(7): e308-16

    Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection.

    Zavaglia C, Silini E, Mangia A, Airoldi A, Piazzolla V, Vangeli M, Stigliano R, Foschi A, Mazzarelli C, Tinelli C


    2014; ():

    Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study.

    Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A


    2013; 58: S476

    Effects of a new liposome-encapsulated formulation of silybin on hepatitis c virus infection

    Ripoli M., Angelico R., Piazzolla V., Santoro R., Mottola L., Petruzzellis D., Mangia A.

    2013; 59(2): 221-8

    Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

    Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C


    2013; 58(1): 65-72

    Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution.

    Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, Piazzolla V, Badea R, Laffi G, Marra F, Mangia A, Pinzani M


    2013; ():

    Reply to: "Built-in bias in HCV clearance in acute hcv infection"

    Copetti M, Pellegrini F, Piazzolla V, Mangia A


    HCV2012 - 19th International Symposium on hepatitis C virus and related viruses 2012; Venezia 5-9 ottobre 2012: p 301

    Effects of silybin on Hepatitis C virus replications: an "in vitro" study

    Ripoli M, Piazzolla V, Mottola L, Santoro R, Petruzzellis D, Mangia A,

    2012; Ottobre 2012 - 1791: 1028a

    Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major tretated for chronic hepatitis C

    Santoro R, Piazzolla V, Mottola L, Dello Iacono N, Mangia A

    2012; ():

    Update on the treatment of patients with non-genotype 1 HCV infection.

    Mangia A, Mottola L, Piazzolla V


    2012; 56 - 1135: s448

    IL28B CC. Genotype is associated with higher on-treatment-response rates in PTS with HCV-3: interim results of the write study

    Piazzolla V, Forte P, Francavilla R, Barbarini G, Mecenate F, Carrado M, Minerva G, Bacca D, Carretta V, Pellicelli A, Romano M, Montalto G, Zignego L, Nosotti L, De Luna A, Agostinacchio E, Cuccorese G, Luchi S, Bertino G, Santoro R, Mottola L, Petruzzel

    2011; 16(8): 1309-16

    IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients.

    Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, Bacca D, Clemente R, Copetti M, di Mauro L, Lotti G, Sacco M, Stefano I


    2011; 54: S525

    Lack of association between IL28B variants and HBSAG clearance after interferon treatment

    Mangia A, Santoro R, Mottola L, Fasano M, Minerva N, Bacca D, Piazzolla V, Carretta V, Termite A, Agostinacchio E, Facciorusso D, Petruzzellis D, Santantonio T

    2011; 54(4): 403A-404A

    Treatment Of Patients With Acute Hcv Monoinfection May Be Delayed After Week 24 According With Il28b Single Nucleotide Polymorphisms (Snp) Results And Independently Of Hepatitis C Virus (Hcv) Genotype

    Mangia A. et al.

    2011; ():

    Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring.

    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG


    2011; 53(2): 389-95

    Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

    Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A


    2011; 54(s1): 339-340

    Genetic predictors of steatosis and fibrosis in non alcoholic fatty liver disease (NAFLD)

    Mangia A, Mottola L, Petruzzellis D, Piazzolla V, Garrubba M, Di Paola R, Santoro R, Trischitta V, Villella M, Fanelli R, Vanni E, Seripa D, Pilotto A, Bugianesi E, Guido M, Santini SA

    {accordionfaq faqid=accordion3 faqclass="lightnessfaq defaulticon headerbackground headerborder contentbackground contentborder round5" active=0}

nuovo-css

webcamlive

Newsletter

Informativa Newsletter
  twitter   facebook   youtube